At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET
Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 million in gross proceeds. The capital will fund development of its QTORIN pipeline, including rapamycin and pitavastatin programs, and support general corporate purposes.
- Palvella closed a public offering of 1,840,000 shares of common stock at $125.00 per share.
- The offering included full exercise of the underwriters' option to purchase 240,000 additional shares.
- Gross proceeds totaled $230 million before underwriting discounts and expenses.
- Proceeds will be used to advance QTORIN rapamycin and QTORIN pitavastatin programs, and for working capital and R&D.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access